Global Leading Institutions Took Stakes in Yeahka, Showing Confidence in Its Long-Term Prospects
HONG KONG--(BUSINESS WIRE)--YEAHKA LIMITED, China’s leading payment and business service technology platform commences trading on…
6 years ago
Aromajoin Announces Six Finalists for Its First Ever Digital Scent-Inspired Hackathon, Hackaroma
Hackaroma is the world's first scent-inspired hackathon. It has decided six finalists for the next…
6 years ago
Integrated Investment Research Quarterly Earnings Report Jan-April 2020
Tokyo, Japan, May 30, 2020 --(PR.com)-- Integrated Investment Research announced their start to the year…
6 years ago
ViaBTC Group Announces Strategic Upgrade to Advance Innovation and Improve Customer Experience
HONG KONG--(BUSINESS WIRE)--ViaBTC Group, an innovative technology company specialized in blockchain and dedicated to providing…
6 years ago
TIS Raises $20m as Demand Grows for Its Leading SaaS B2B Payment Platform
Investment from Aquiline and 83North will be used to continue rapid global expansion. Walldorf, Germany,…
6 years ago
Ares is Only Taiwan Commercial Service Vendor Certified by ISDA SIMM™
Taipei, Taiwan, May 30, 2020 --(PR.com)-- Ares International Corp. was recently certified by International Swaps…
6 years ago
Crash Barrier Systems Market 2020-2024 | Implementation of Road Safety Programs to Boost Market Growth | Technavio
LONDON--(BUSINESS WIRE)--#CrashBarrierSystemsMarket--The crash barrier systems market is expected to grow by USD 1.29 billion during…
6 years ago
Dr. Jacob Frydman Online Pet Care Offers Veterinary Services for Non-Critical Pet Care Issues
Most non-critical pet care issues can be addressed & diagnosed online. An experienced veterinarian from…
6 years ago
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
61.9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved…
6 years ago
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
TOKYO & BASKING RIDGE, N.J. & MUNICH--(BUSINESS WIRE)--Results from the phase 2 DESTINY-CRC01 trial of…
6 years ago